Sat, Sep 20, 2014, 10:51 PM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Ampio Pharmaceuticals, Inc. Message Board

  • sirmichael222 sirmichael222 Feb 26, 2013 1:04 PM Flag

    My Personal Opinion on AMPE's drug, Ampion.

    Ampion is a treatment with much potential. It has already been reported to be effective in patients within a few hours and to have been still effective at the 12 week point (exactly 84 days) after injection. This suggests that it might need to be administered no more than about four (4) times a year. Hence the question arises: Might it be able to be administered less often, say twice a year? Would using a larger dosage facilitate that? Hence the FDA request to include a sample of patients receiving the higher dosage. AMPE appears to me to be quite undervalued.

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • What do you mean by " have been still effective at the 12 week point (exactly 84 days) after injection"?

      If you look at the presentation on AMPE's website (slide 11), it clearly shows that there was no statistically significant difference between saline and ampion at days 3, 8, and 30 after injection.

      • 1 Reply to ampiooooooh
      • ampiooooooh, once again you are deceiving this board with your short tactics. The chart in slide 11 clearly indicates that overall the PAIN LEVEL was much much lower compared to saline. Compared to patients that were injected with saline, Ampio showed a huge reduction in pain starting in day 8 and stayed low and almost constant all the way till day 84. Pain in patients that were injected with saline was skyrocketed starting in day 8. Now go look elsewhere for your pray.

        Sentiment: Strong Buy

 
AMPE
3.48+0.04(+1.16%)Sep 19 4:03 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.